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Abstract
Whole genome sequencing was used to characterize the resistome of intensive care unit (ICU) outbreak-associated
carbapenem-resistant K. pneumoniae isolates. Importantly, and of particular concern, the carbapenem-hydrolyzing b-
lactamase gene blaOXA-48 and the extended-spectrum b-lactamase gene blaCTX-M-14, were identified on a single broad host-
range conjugative plasmid. This represents the first report of blaOXA-48 in Australia and highlights the importance of
resistance gene surveillance, as such plasmids can silently spread amongst enterobacterial populations and have the
potential to drastically limit treatment options. Furthermore, the in vivo evolution of these isolates was also examined after
18 months of intra-abdominal carriage in a patient that transited through the ICU during the outbreak period. Reflecting the
clonality of K. pneumoniae, only 11 single nucleotide polymorphisms (SNPs) were accumulated during this time-period and
many of these were associated with genes involved in tolerance/resistance to antibiotics, metals or organic solvents, and
transcriptional regulation. Collectively, these SNPs are likely to be associated with changes in virulence (at least to some
extent) that have refined the in vivo colonization capacity of the original outbreak isolate.
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Introduction
Klebsiella pneumoniae is a common cause of infections worldwide,
both in community and hospital settings [1,2]. Based on data from
the Study for Monitoring Antimicrobial Resistance Trends
(SMART), carbapenems remain the most effective treatment
option for these infections, especially those caused by strains
producing extended-spectrum b-lactamases (ESBLs) [1,2]. While
the occurrence of ESBL-producing K. pneumoniae infections has
been variable over the past decade, there has been an overall
increase in the number of these strains [1,3]. The consequence of
ESBL-associated infections is a greater reliance on carbapenems as
one of the few remaining effective agents. Therefore, the
emergence of carbapenem-resistant K. pneumoniae is particularly
worrisome, as not only are treatment options limited but these
infections are associated with increased morbidity and mortality
[4,5].
In Australia, carbapenem resistance in K. pneumoniae is un-
common and over the past decade has generally been secondary to
the expression of metallo-b-lactamase (MBL) genes (specifically
blaIMP-4) [6], in combination with changes in outer-membrane
porins. Recently, two K. pneumoniae isolates have been reported that
produce either the MBL NDM-1 [7] or an Ambler Class A KPC-
type carbapenem-hydrolyzing b-lactamase [8]. Furthermore, with
respect to Enterobacteriaceae, Ambler class D carbapenem-hydrolyz-
ing b-lactamase (CHDL) genes have also recently emerged in
Australia with the report of a clinical K. pneumoniae isolate carrying
a plasmid with blaOXA-181 [9]. However, a related gene, blaOXA-48,
which was first identified in a K. pneumoniae isolate from Turkey in
2001 [10], and that has spread to Africa, Asia and Europe, has not
previously been detected in Australia [11]. The broad dissemina-
tion of blaOXA-48, which has largely been due to an association with
plasmid-borne Tn1999 or related transposons [11], is of major
concern given the ease at which transmission and spread occurs
and the subsequent consequence for therapy.
In this study we used whole genome sequencing to characterize
the resistome of the first known OXA-48 producing carbapenem-
resistant K. pneumoniae isolates following an introduction resulting
in an outbreak in a metropolitan Sydney Intensive Care Unit
(ICU). In addition, we examine the in vivo evolution of this strain
based on recovery of the same isolate from an ‘‘outbreak’’ patient
following 18 months of carriage.
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Methods
Bacterial Strains, Growth Conditions and Antibiotic
Resistance Profiles
Isolates: In 2010, a multi-drug carbapenem-resistant K. pneumoniae
(Kp001) was introduced into the ICU of a Sydney Metropolitan
Hospital by a patient recently returned from Egypt. Three additional
patients acquired the organism over several months before termina-
tionof theoutbreak.All fourpatientswhodevelopedan infectionwith
this organism died. However, 18 months later, a similarK. pneumoniae
isolate (Kp002) was recovered from the abdominal fluid of a patient
(post-hernia repair) who had transited through the ICU at the time of
the initialoutbreak,despitenegativerectal screeningswabsat thetime
of the outbreak. Upon referral to a reference laboratory, both isolates
were indistinguishable by either antibiotic resistance profiling or
molecular diagnostics (pulsed-field gel electrophoresis and entero-
bacterial repetitive intergenic consensus sequence PCR; data not
shown).
Bacterial strains used in this study are listed in Table 1. Bacterial
strains were grown at 37uC in LB medium (Sigma-Aldrich; St. Louis,
USA) or on plates containing LB medium and 1.5% w/v agar
(Amresco; Solon, USA), unless otherwise stated. When required,
media was supplemented with 100 mg mL21 ampicillin (Amresco;
Solon, USA) and/or 100 mg mL21 rifampicin (Sigma-Aldrich; St.
Louis, USA). Antibiotic resistance profiles were determined on
a VITEK 2 AST-N149 card using the global and natural resistance
interpretive criteria (bioMérieux; Marcy L’Étoile, FRA).
DNA Manipulations
DNA was extracted from K. pneumoniae and Escherichia coli cells
using the ISOLATE Genomic DNA and Plasmid Mini Kits
(Bioline; London, UK), respectively. DNA fragments were PCR-
amplified using BioTaq (Bioline; London, UK) and primer pairs
described in Table 1. Capillary sequencing of PCR products was
performed by Macrogen Inc (Seoul, KOR).
Whole Genome Sequencing
Kp001 DNA was sent to The Ramaciotti Centre (University of
New South Wales; Sydney, AUS) for sequencing on an Illumina
HiSeq 2000 system (Illumina Inc; San Diego, USA). A fragment
library of Kp002 DNA was generated and sequenced on an Ion
Torrent PGM (Life Technologies; Carlsbad, USA) according to
the manufacturer’s instructions. Analysis of Kp001 and Kp002
genomic data was performed using CLC Genomics Workbench
5.5 (CLC bio; Katrinebjerg, DEN). Reference mapping of reads to
the genome of the non-multi-drug resistant K. pneumoniae strain
NTUH-K2044 (GenBank accession no. AP006725) facilitated
variant analysis using a quality-based algorithm (as implemented
in CLC Genomics Workbench) applying an 80% genotype
frequency cutoff with a minimum coverage of 10 reads.
Homopolymer variants as well as variants present in both
Kp001 and Kp002 were excluded. The remaining variants were
curated manually to ensure accurate identification. Raw data for
this project has been uploaded to the Sequencing Read Archive
under accession number SRA062913. A de novo assembly of reads
that did not map to NTUH-K2044 was used to query an in-house
database (constructed within CLC Genomics Workbench) of
clinically relevant antibiotic resistance genes (see Table S1).
BLASTn analyses of resultant contigs using the NCBI non-
redundant nucleotide database were also performed in order to
examine the genetic context of identified resistance determinants.
Gaps in plasmid read mappings were closed via PCR amplification
and capillary sequencing.
Conjugation Experiments
Filter-based conjugation experiments were performed as pre-
viously described [12] using a rifampicin-resistant mutant Escher-
ichia coli DH5a strain (Ec002), which was obtained via growth on
an LB agar plate containing 100 mg mL21 rifampicin.
Table 1. Bacterial strains, plasmids and primers.
Strain, plasmid or primer Genotype, relevant characteristics or sequence Source
Strains E. coli
Ec002 RifampicinR derivative of DH5a: F- endA hsdR17 supE44 thi-1 l- recA1 gyrA96 relA1 w80 dLacZDM15 This study
Ec003 Ec002 carrying pJEG011 and pJEG012 This study
K. pneumoniae Kp001 Clinical outbreak-associated isolate carrying pJEG011 and pJEG012 This study
Kp002 Clinical outbreak-associated isolate phenotypically and genotypically indistinguishable from Kp001: isolated
after 18 months of intra-abdominal carriage
This study
Plasmids
pJEG011 IncL/M, Tn1999, ISEcp1-blaCTX-M-14, Tn5393jD This study
pJEG012 pir, Tn1331 This study
Primers
aacA4-F 59- gaagagtatgagtattcaaacatttcc -39 This study
aacA4-R 59- ggaagggttaggcaacac -39 This study
aacC2-F 59- gtttagaggagatatcgcgatg-39 This study
aacC2-R 59- ttgtcgacggcctctaac-39 This study
CTX-M-14-F 59- gagagtgcaacggatgatg -39 This study
CTX-M-14-R 59- tgcggctgggtaaaatag -39 This study
OXA-48-F 59- gcttccaccctaatttgatg -39 This study
OXA-48-R 59- cgagcatcagcattttgtc -39 This study
doi:10.1371/journal.pone.0059920.t001
Genome Analysis of K. pneumoniae Outbreak Isolates
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Results and Discussion
Defining the Common Resistome
The mobile resistome. Both Kp001 and Kp002 were
shown to be resistant to aminoglycosides and most b-lactams
including, and of particular concern, meropenem. In order to fully
define the resistome for both isolates, WGS reads that did not map
to NTUH-K2044 were de novo assembled and examined via
BLASTn analysis using an in-house database (created within CLC
Genomics Workbench 5.5) of known antibiotic resistance
determinants in Gram-negative bacteria (see Methods). Included
in the local resistance gene database (RGD) were representative
alleles of common aminoglycoside resistance genes [13,14],
quinolone resistance genes [15] and b-lactam resistance genes,
including those that encode extended-spectrum and carbapenem-
hydrolyzing b-lactamases [16–20]. Further BLASTn analysis and
reference mapping was then performed in order to determine the
genetic context of the identified determinants.
Based on interrogation of the RGD, four b-lactamase genes
were identified in both Kp001 and Kp002: blaSHV-1 (which is
ubiquitous in K. pneumoniae), blaCTX-M-14 (which differs from
blaCTX-M-9 by 4 nucleotides), blaOXA-9 and, of particular impor-
tance, the blaOXA-48 CHDL gene. Further analysis revealed
blaCTX-M-14 was present as part of an ISEcp1 transposition unit
which had inserted into a plasmid designated pJEG011 (GenBank
accession no. KC354801). pJEG011 shares .95% nucleotide
sequence similarity with the backbone structure of the multi-
resistance IncL/M conjugative plasmid pOXA-48a (GenBank
accession no. JN626286) (11), including Tn1999 containing the
blaOXA-48 gene [21] (Figure 1A).
Figure 1. Structural features of plasmids pJEG011 and pJEG012. Comparisons to related plasmids pOXA-48a (A) and pJIE143 (B) are shown,
respectively; plasmid backbones are represented by thick gray lines and areas of $99% sequence identity between plasmids are indicated by the
light blue areas. Only the following selected genes are annotated and represented by colored arrows: plasmid replication genes, red; transposon-
related genes, orange; plasmid partitioning, maintenance (e.g., toxin/antitoxin systems (T/AT)), mobilization and conjugation genes, yellow;
aminoglycoside resistance genes, green; b-lactam resistance genes, blue. Dashed arrows represent more than one gene or open reading frame.
Insertion sequences (IS) are represented by orange pentagons with the IS number indicated within; the direction of the IS with respect to the
transposase gene is indicated by the point of the pentagon. Inverted repeats associated with IS and transposons are indicated by vertical orange
lines; the nucleotide sequences of the direct repeats resulting from IS and transposon insertion are indicated above or below the plasmid figures.
Integron gene cassettes are represented by orange rectangles.
doi:10.1371/journal.pone.0059920.g001
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The aminoglycoside resistances genes aphA6 and strAB were also
present as part of pJEG011, and were located within a novel
Tn5393 module (Figure 1A). The other aminoglycoside resistance
genes detected (aacC2, aacA4 and aadA1) were not part of pJEG011.
Further analysis revealed that the aacC2 gene was located on
a contig that is flanked by two copies of IS26 in the same
orientation as previously described for certain IncFII plasmids
[22], however the genetic context of this determinant remained
unclear. In contrast, both the aacA4 and aadA1 genes were located
on the same contig along with blaOXA-9, and these were all present
as part of Tn1331. Further examination of this contig revealed
that Tn1331 had inserted into a pir-type plasmid designated
pJEG012 (GenBank accession no. KC354802), which shares
.85% nucleotide sequence similarity with the backbone structure
of another plasmid, pJIE143 (GenBank accession no. JN194214)
[23]; pJEG012 also contained a putative toxin/anti-toxin system
and a single copy of IS26 (Figure 1B).
Contribution of single nucleotide variants. Both isolates
had SNPs in gyrA and parC, which encode subunits of DNA gyrase
and topoisomerase IV, respectively, and are involved in DNA
replication and segregation. These SNPs result in amino acid
changes within the quinolone resistance determining regions of
GyrA (S80I) and ParC (S83Y and D87G), and collectively are
known to confer high-level resistance to ciprofloxacin and nalidixic
acid [24].
Transfer of the Mobile Resistome
Conjugation experiments revealed that pJEG011 and pJEG012
could be readily transferred from Kp001 to Ec002. The presence
of both plasmids in a single E. coli transconjugant, Ec003, was
determined by PCR amplification of blaCTX-M-14, blaOXA-48 and
aacA4 (Table 2). The aacC2 gene was not detected by PCR in the
transconjugant (in agreement with the above analysis), suggesting
that it is most likely located on the chromosome. Despite increased
b-lactam MICs, Ec003 was fully susceptible to meropenem
(Table 2). This was not unexpected as OXA-48 only hydrolyzes
carbapenems at low levels [10].
In K. pneumoniae, carbapenem resistance in the setting of OXA-
48 production is usually co-dependent upon the presence of
additional mechanisms of resistance, such as outer membrane
porin defects. These mutations generally occur within the
OmpK35 and OmpK36 porins, which allow carbapenem entry
into the cell. Analysis of the isolates revealed that ompK35 was
truncated via a 485 bp chromosomal deletion (nt 1,880,269–
1,880,753) while ompK36 contained a duplication of the sequence
GGCGAC (nt 1,879,495–1,879,500). This duplication would most
likely result in partial occlusion of the OmpK36 channel as a result
of insertion of two additional amino acids into loop 3 [25].
In vivo Evolution
Kp001 and Kp002 were considered identical based on their
antibiotic resistance profiles (Table 3), molecular (see methods;
data not shown) and in silico multi-locus sequence typing [26]
which revealed that both isolates belonged to ST101. Nucleotide
variant analysis revealed that Kp001 and Kp002 differed by 11
single nucleotide polymorphisms (SNPs; Table 4), many of which
are associated with proteins involved in tolerance/resistance to
antibiotics, metals or organic solvents, and transcriptional
regulation.
Compared to Kp001, a SNP in Kp002 was observed in a region
of rpoB known to contribute to rifampicin resistance [27].
Subsequently, rifampicin resistance was demonstrated in vitro for
Kp002, but not Kp001 (wild-type rpoB), as it could be cultured on
LB agar containing 100 mg mL21 rifampicin. In Australia, it is
common practice to soak the surgical mesh in a solution of
rifampicin prior to surgery as an infection prevention measure.
This exposure most likely contributed to the in vivo selection of the






Ampicillin $32 $32 #2
Amoxicillin/CLA $32 16 #2
Ticarcillin/CLA $128 $128 #8
Piperacillin/TZB $128 $128 #4
Cefazolin $64 $64 #4
Cefoxitin $64 #4 #4
Ceftazidime 4 #1 #1
Ceftriaxone $64 32 #1
Cefepime $64 #1 #1
Meropenem $16 #0.25 #0.25
Gene Target PCR Results
aacA4 + + 2
blaCTX-M-14 + + 2
blaOXA-48 + + 2
aacC2 + 2 2
aAntibiotic abbreviations: CLA, clavulanic acid, TZB, tazobactam.
bMICs were determined using a VITEK 2 AST-N149 card.
doi:10.1371/journal.pone.0059920.t002






















aAntibiotic abbreviations: CLA, clavulanic acid, TZB, tazobactam; TMP/SXT,
trimethoprim/sulfamethoxazole.
bMICs were determined using a VITEK 2 AST-N149 card.
doi:10.1371/journal.pone.0059920.t003
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rpoB mutation as Kp002 was isolated from the patients’ intra-
abdominal mesh associated collection post hernia repair.
In Kp002, a SNP in gyrI resulted in an amino acid change that
may affect protein activity and play a role in decreased quinolone
susceptibility. Although overexpression of gyrI (aka sbmC), has been
shown to confer protection against quinolones and toxin/anti-
toxin plasmid maintenance systems in E. coli [28], it is unlikely to
have had much additional effect in our isolate given the high level
quinolone resistance mutations already present.
In the context of regulation, two SNPs were associated with
LysR-type transcriptional regulators (LTTRs), which represent the
largest group of transcriptional regulators regulating genes/
pathways associated with metabolism, motility, quorum sensing
and virulence [29]. The amino acid change in the gene product of
locus KP1_0101 is flanked by amino acids involved in di-
merization, based on the conserved domain database [30],
suggesting that this mutation is likely to have functional
significance. Furthermore, the mutation upstream of the other
putative LTTR gene (locus KP1_3109; Table 4) may have
a bearing on promoter activity, as it is located 35 bp upstream of
the start codon. In addition, there is also a SNP present in slyA,
which encodes a known transcriptional regulator of virulence
genes. SlyA is involved in conferring resistance to antimicrobial
peptides and oxidative stress in salmonellae [31,32] as well as
regulation of fimbriae in E. coli, which have an important role in
colonization and pathogenesis [33]; based on the crystal structure
of SlyA, the resulting amino acid change (V120G) is located
between two a-helices involved in dimerization [34]. Although the
functional consequences of these mutations are not directly known,
it is interesting that they occurred during 18 months of intra-
abdominal carriage after an initial outbreak event that resulted in
patient deaths. As such, it is likely that they are collectively
associated with changes in virulence (at least to some extent) that
have refined the in vivo colonization capacity of Kp002. In this
context it is relevant to note that Young et al., [35] recently
suggested that truncation of a Staphylococcus aureus transcriptional
regulator (implicated in pathogenicity) after 13 months of carriage,
was a key factor driving changes in virulence capacity.
Concluding Remarks
To the best of our knowledge, this study represents the first
report of the blaOXA-48 CHDL gene in Australia. This study also
illustrates the in vivo evolution of a multidrug-resistant K. pneumoniae
isolate during 18 months of carriage. Of note, some of the SNPs
identified, particularly those associated with transcriptional reg-
ulators, may be involved in modulation of Kp002 virulence
capacity. In a global context, this is also the first report of blaCTX-
M-14 and blaOXA-48 co-residing on a single broad host-range
conjugative plasmid (i.e., pJEG011). While international travel has
facilitated the clonal spread of blaOXA-48-containing K. pneumoniae
ST101 isolates [36–38], especially from countries along the
Mediterranean Sea, the presence of blaOXA-48 within Tn1999
(and related transposons) on different Inc group plasmids
[21,39,40], has played a crucial role in its dissemination. The
emergence of plasmids such as pJEG011, and the one recently
described by Potron et al. [41], is of great clinical concern as they
have the potential to more broadly disseminate resistance
associated with these determinants. In this respect, it is also
concerning that these determinants have the potential to go
undetected based on antibiotic susceptibility profiles. Therefore,
this study highlights the importance of surveillance based on
resistance screening, especially in environments where antibiotic
selection pressure is prevalent.
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Table S1 List of antibiotic resistance genes used in the
in-house database for resistome determination.
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